NCT05249114 2026-04-13
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Providence Health & Services
Phase 1 Active not recruiting
Clinical Trials
12 trialsNCT04261855 2026-03-27
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Active not recruiting
NCT07145177 2026-03-23
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT07150546 2026-03-02
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
Phase 1 Recruiting
NCT06105918 2025-12-09
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
Emory University
Phase 1 Active not recruiting
NCT06320067 2025-09-26
STAMPEDE2
University College, London
Phase 3 Recruiting
NCT06878664 2025-09-02
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT06199453 2025-02-10
LuRM_ACC/2023
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Withdrawn
NCT06449781 2025-02-10
PSMA-ADJUVO
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Recruiting
NCT04949282 2022-12-23
SEPTRALU
Sociedad Española de Medicina Nuclear e Imagen Molecular
Recruiting
NCT04790708 2021-03-10
FENET-2016
University Hospital of Ferrara
Phase NA Unknown
NCT00860860 2012-03-19
PRIT2008
Radboud University Medical Center
Phase 1 Completed